Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marn, C. S.
Right arrow Articles by Ensminger, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marn, C. S.
Right arrow Articles by Ensminger, W. D.

Radiology, Vol 187, 125-128, Copyright © 1993 by Radiological Society of North America


ARTICLES

Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings

CS Marn, JC Andrews, IR Francis, MD Hollett, SC Walker and WD Ensminger
Department of Diagnostic Radiology, University of Michigan Hospital, Ann Arbor 48109-0030.

The serial contrast material-enhanced computed tomographic scans of 23 patients treated with intraarterial yttrium-90 microspheres as therapy for hepatic metastatic disease were reviewed for evidence of parenchymal changes in the liver in areas not involved with tumor. Irregular low-attenuation geographic areas that developed in the hepatic parenchyma after therapy were graded as mild, moderate, or severe and were evident in 12 of 23 patients. In nine cases of mild to moderate changes in the hepatic parenchyma, the abnormality was either focal or asymmetric. In all three patients receiving the highest dose (15,000 cGy), severe diffuse parenchymal changes were seen in all hepatic segments. In the remaining 11 patients, no parenchymal changes were seen. The most pronounced changes were seen at 8 weeks after therapy and were partially or completely reversible at 16-24 weeks. All patients had minimal or no change in liver function and no clinical sequelae attributable to liver injury.


This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
F. H. Miller, A. L. Keppke, D. Reddy, J. Huang, J. Jin, M. F. Mulcahy, and R. Salem
Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET
Am. J. Roentgenol., March 1, 2007; 188(3): 776 - 783.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
R. Murthy, R. Nunez, J. Szklaruk, W. Erwin, D. C. Madoff, S. Gupta, K. Ahrar, M. J. Wallace, A. Cohen, D. M. Coldwell, et al.
Yttrium-90 Microsphere Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential Complications
RadioGraphics, October 1, 2005; 25(suppl_1): S41 - S55.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1993 by the Radiological Society of North America.